Q1 FY27 results analysis · July 31, 2026

Ajanta Pharma Q1 FY27 Results Analysis: US Generics Surge 57%, Asia Generics Decline 16% (AJANTPHARM)

+30.9%PAT year on year, Rs. 334.22 Cr
Cofacto ResearchPublished July 31, 20262 min readPositive read
Quick summary

Ajanta Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,625.96 Cr (+24.82% YoY) and PAT growth of +30.89% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 30, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 1,625.96 Cr (+24.82% YoY)
PAT (Q1)Rs. 334.22 Cr (+30.89% YoY)
EBITDA margin26.05% (-92 bps YoY)
EPS (Q1)Rs. 26.75 (+30.87% YoY)
Market capRs. 42,932.88 Cr
CMPRs. 3,436.40

Quarter Snapshot

Ajanta Pharma delivered a strong Q1 with 24.8% revenue growth and 30.9% PAT growth, driven by a massive 57% surge in US generics (far above guidance) and India branded generics outperforming the market. However, Asia branded generics declined 16% (missed guidance) and the effective tax rate rose. The company's adjusted EBITDA margin of 28.0% was within guidance, and the dividend was raised. Overall, a solid quarter with a key growth surprise in US, but Asia remains a concern.

Key Investment Insights

Key Positives

  • Revenue grew 24.8% YoY to Rs.1,625.96 Cr, highest quarterly growth in at least five quarters.
  • PAT grew 30.89% YoY to Rs.334.22 Cr, EPS at Rs.26.75.
  • US Generics revenue grew 57% YoY, far exceeding management's mid-single-digit guidance.
  • India branded generics grew 24% YoY, outperforming IPM growth of 11%.
  • Adjusted EBITDA margin of 28.0% was within the guided band of 27%±1%.
  • Interim dividend raised to Rs.32 per share from Rs.28 per share.
  • 3 ANDA approvals received in Q1, with 2 launched.

Risk Factors

  • Asia branded generics declined 16% YoY, missing management's low double-digit growth guidance.
  • Effective tax rate rose to 25.20% from 22.89% in Q1 FY26 due to one manufacturing facility transitioning out of tax exemption.
  • Forex volatility remains lumpy; net gain this quarter but reported EBITDA margin compressed 92 bps YoY to 26.05% due to forex losses.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.